APA (7th ed.) Citation

M, T., Y, M., T, K., T, O., T, S., S, H., . . . J, F. (2025). Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 23(3), 102322. https://doi.org/10.1016/j.clgc.2025.102322

Chicago Style (17th ed.) Citation

M, Takahashi, et al. "Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma." Clinical Genitourinary Cancer 23, no. 3 (2025): 102322. https://doi.org/10.1016/j.clgc.2025.102322.

MLA (9th ed.) Citation

M, Takahashi, et al. "Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma." Clinical Genitourinary Cancer, vol. 23, no. 3, 2025, p. 102322, https://doi.org/10.1016/j.clgc.2025.102322.